Cantor Fitzgerald Reiterates a Buy Rating on Nabriva

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Nabriva (NASDAQ: NBRV) today and set a price target of $16. The company’s shares opened today at $4.79, close to its 52-week low of $4.39.

Chen wrote:

“Positives from the quarter: 1) On 3/27/2018, NBRV and Roivant Sciences (private) announced a collaboration agreement to develop and commercialize lefamulin in greater China. 2) On 03/21/18, NBRV announced the appointment of Jennifer Schranz, M.D., as Chief Medical Officer. Dr. Schranz joins Shire plc (SHPG, Overweight), with nearly two decades of experience in clinical development and medical affairs. She joins the company in advance of the availability of topline results of the second Phase 3 global clinical trial for lefamulin which are expected in the Spring of 2018. Dr.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -11.3% and a 37.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.

Nabriva has an analyst consensus of Moderate Buy, with a price target consensus of $13.

See today’s analyst top recommended stocks >>

The company has a one-year high of $14.10 and a one-year low of $4.39. Currently, Nabriva has an average volume of 280.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic available for systemic administration in humans.